COMMUNIQUÉS West-GlobeNewswire
-
Tevogen Bio Announces Series A-1 Preferred Stock Investment
27/03/2024 - 14:20 -
Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00
27/03/2024 - 14:20 -
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
27/03/2024 - 14:20 -
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
27/03/2024 - 14:36 -
XORTX Announces New Clinical Advisory Board Member
27/03/2024 - 10:00 -
Zymeworks Announces Participation in Upcoming Investor Conferences
27/03/2024 - 11:00 -
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
27/03/2024 - 11:30 -
26 Patient Volunteer Leaders Attend the Foundation for Sarcoidosis Research Global Sarcoidosis Clinic Alliance Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic
27/03/2024 - 11:41 -
ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP
27/03/2024 - 11:50 -
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA
27/03/2024 - 07:00 -
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
27/03/2024 - 07:00 -
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate
27/03/2024 - 07:30 -
Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma
27/03/2024 - 07:45 -
Convocation à l'assemblée générale ordinaire du 26/04/2024
27/03/2024 - 08:00 -
Convening of the ordinary general meeting of shareholders of April 26, 2024
27/03/2024 - 08:00 -
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
27/03/2024 - 00:00 -
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
26/03/2024 - 21:00 -
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
26/03/2024 - 21:01 -
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26/03/2024 - 21:01
Pages